🚀 VC round data is live in beta, check it out!
Shandong Weigao Blood Valuation Multiples
Discover revenue and EBITDA valuation multiples for Shandong Weigao Blood and similar public comparables like Dentsply Sirona, Inner Mongolia Furui Medical Science, Schott Pharma, Haemonetics and more.
Shandong Weigao Blood Overview
About Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
Founded
2004
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Shandong Weigao Blood Financials
Shandong Weigao Blood reported last 12-month revenue of $558M and EBITDA of $120M.
In the same LTM period, Shandong Weigao Blood generated $225M in gross profit, $120M in EBITDA, and $71M in net income.
Revenue (LTM)
Shandong Weigao Blood P&L
In the most recent fiscal year, Shandong Weigao Blood reported revenue of $552M and EBITDA of $121M.
Shandong Weigao Blood expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $558M | XXX | $552M | XXX | XXX | XXX |
| Gross Profit | $225M | XXX | $222M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | $120M | XXX | $121M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $71M | XXX | $71M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Shandong Weigao Blood Stock Performance
Shandong Weigao Blood has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Shandong Weigao Blood's stock price is $5.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.8% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShandong Weigao Blood Valuation Multiples
Shandong Weigao Blood trades at 3.4x EV/Revenue multiple, and 15.8x EV/EBITDA.
EV / Revenue (LTM)
Shandong Weigao Blood Financial Valuation Multiples
As of April 11, 2026, Shandong Weigao Blood has market cap of $2B and EV of $2B.
Equity research analysts estimate Shandong Weigao Blood's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shandong Weigao Blood has a P/E ratio of 32.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 22.2x | XXX | 22.4x | XXX | XXX | XXX |
| EV/Gross Profit | 8.4x | XXX | 8.5x | XXX | XXX | XXX |
| P/E | 32.6x | XXX | 32.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 20.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shandong Weigao Blood Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shandong Weigao Blood Margins & Growth Rates
Shandong Weigao Blood's revenue in the last 12 month grew by 8%.
Shandong Weigao Blood's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shandong Weigao Blood's rule of X is 38% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Shandong Weigao Blood Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 38% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Shandong Weigao Blood Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dentsply Sirona | XXX | XXX | XXX | XXX | XXX | XXX |
| Inner Mongolia Furui Medical Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Haemonetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Chengzhi | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shandong Weigao Blood M&A Activity
Shandong Weigao Blood acquired XXX companies to date.
Last acquisition by Shandong Weigao Blood was on XXXXXXXX, XXXXX. Shandong Weigao Blood acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Shandong Weigao Blood
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialShandong Weigao Blood Investment Activity
Shandong Weigao Blood invested in XXX companies to date.
Shandong Weigao Blood made its latest investment on XXXXXXXX, XXXXX. Shandong Weigao Blood invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Shandong Weigao Blood
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shandong Weigao Blood
| When was Shandong Weigao Blood founded? | Shandong Weigao Blood was founded in 2004. |
| Where is Shandong Weigao Blood headquartered? | Shandong Weigao Blood is headquartered in China. |
| Is Shandong Weigao Blood publicly listed? | Yes, Shandong Weigao Blood is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Shandong Weigao Blood? | Shandong Weigao Blood trades under 603014 ticker. |
| When did Shandong Weigao Blood go public? | Shandong Weigao Blood went public in 2025. |
| Who are competitors of Shandong Weigao Blood? | Shandong Weigao Blood main competitors are Dentsply Sirona, Inner Mongolia Furui Medical Science, Schott Pharma, Haemonetics. |
| What is the current market cap of Shandong Weigao Blood? | Shandong Weigao Blood's current market cap is $2B. |
| What is the current revenue of Shandong Weigao Blood? | Shandong Weigao Blood's last 12 months revenue is $558M. |
| What is the current revenue growth of Shandong Weigao Blood? | Shandong Weigao Blood revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Shandong Weigao Blood? | Current revenue multiple of Shandong Weigao Blood is 3.4x. |
| Is Shandong Weigao Blood profitable? | Yes, Shandong Weigao Blood is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shandong Weigao Blood? | Shandong Weigao Blood's last 12 months EBITDA is $120M. |
| What is Shandong Weigao Blood's EBITDA margin? | Shandong Weigao Blood's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Shandong Weigao Blood? | Current EBITDA multiple of Shandong Weigao Blood is 15.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.